Search

ETC-1001

ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.

CX-046684

CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.

V1003

V1003 is an intranasal formulation of buprenorphine, an opiate analgesic, for the management of post-operative pain in hospital and home settings. … Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both

Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen

Belnacasan

VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.

Dental Mesenchymal Pulp Stem Cells

These cells have innate neurogenic potential as their origins are traced to the embryonic neural crest; there is potential for these cells to create neurons and glial cells. … DPSCs have multiple properties, and express surface antigens like CD90, CD29, and CD105 but not CD14 or CD45.

Cefradine

A semi-synthetic cephalosporin antibiotic.

Interferon alfa

Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography. … Natural interferon alpha or Multiferon is obtained from the leukocyte fraction of human blood following induction with Sendai virus.

Triazavirin

[L12087] Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19.[A191625]

Oxilofrine

It is currently marketed in Canada by Valeant under the tradename Cophylac.